| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/NEN.0B013E3181DDD404 |
| P698 | PubMed publication ID | 20467334 |
| P50 | author | Susanne Petri | Q67224132 |
| Reinhard Dengler | Q67224134 | ||
| Sonja Schmalbach | Q114410653 | ||
| Alexander Sarlette | Q114410654 | ||
| P2093 | author name string | Claas Janssen | |
| Sebastian Boeselt | |||
| P2860 | cites work | Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family | Q24294179 |
| Genomewide studies of histone deacetylase function in yeast | Q27934387 | ||
| Histone acetylation in chromatin structure and transcription | Q28131749 | ||
| Deacetylation of p53 modulates its effect on cell growth and apoptosis | Q28138967 | ||
| Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy | Q28201294 | ||
| Duration of nuclear NF-kappaB action regulated by reversible acetylation | Q28215080 | ||
| HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS | Q28306195 | ||
| Histone deacetylase 11 regulates oligodendrocyte-specific gene expression and cell development in OL-1 oligodendroglia cells | Q28580239 | ||
| Comparative analysis of the time-dependent functional and molecular changes in spinal cord degeneration induced by the G93A SOD1 gene mutation and by mechanical compression | Q30484665 | ||
| HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration | Q34697419 | ||
| HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. | Q35968237 | ||
| RNA synthesis and histone acetylation during the course of gene activation in lymphocytes | Q36457890 | ||
| Mutations in String/CDC25 inhibit cell cycle re-entry and neurodegeneration in a Drosophila model of Ataxia telangiectasia | Q36585497 | ||
| Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection | Q36959335 | ||
| HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment | Q37039472 | ||
| The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance | Q37586967 | ||
| Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords--screening by molecular indexing and subsequent cDNA microarray analysis | Q38361317 | ||
| Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model | Q40128564 | ||
| Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation | Q40152899 | ||
| Distribution of histone deacetylases 1-11 in the rat brain | Q40225359 | ||
| Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. | Q40323686 | ||
| Pre‐and Postmortem Influences on Brain RNA | Q40487622 | ||
| Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration | Q40580109 | ||
| Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis | Q41186937 | ||
| In situ hybridization demonstrates the stability of mRNA in post-mortem rat tissues | Q41921389 | ||
| Developmental expression of histone deacetylase 11 in the murine brain | Q42071643 | ||
| Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin | Q42829173 | ||
| Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis | Q44299705 | ||
| Distribution of GABAAReceptor mRNA in the Motor Cortex of ALS Patients | Q44629514 | ||
| Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease | Q45115023 | ||
| Benefit of valproic acid in suppressing disease progression of ALS model mice | Q45173088 | ||
| Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice | Q46526611 | ||
| Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis | Q46805732 | ||
| Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. | Q47860803 | ||
| Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. | Q48732598 | ||
| Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. | Q51131871 | ||
| P433 | issue | 6 | |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| P304 | page(s) | 573-581 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Journal of Neuropathology & Experimental Neurology | Q15716771 |
| P1476 | title | Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis | |
| P478 | volume | 69 |
| Q37712624 | ALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular Vesicles |
| Q37249167 | Acetyltransferases (HATs) as targets for neurological therapeutics |
| Q38431759 | Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. |
| Q48139092 | Antagonistic molecular interactions of photosynthetic pigments with molecular disease targets: a new approach to treat AD and ALS. |
| Q36599581 | Chromatin deregulation in disease. |
| Q92410530 | Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models |
| Q45388639 | Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? |
| Q101237411 | Disruption of Tip60 HAT mediated neural histone acetylation homeostasis is an early common event in neurodegenerative diseases |
| Q28080897 | Dynamic self-guiding analysis of Alzheimer's disease |
| Q50993029 | Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis. |
| Q36405886 | Epigenetic mechanisms governing the process of neurodegeneration |
| Q35953122 | Epigenetic mechanisms in memory and synaptic function. |
| Q29616621 | Epigenetic protein families: a new frontier for drug discovery |
| Q37870034 | Epigenetic regulation of gene expression in physiological and pathological brain processes |
| Q58571293 | Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease |
| Q91811242 | Existing and Emerging Metabolomic Tools for ALS Research |
| Q94686423 | HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo |
| Q27679266 | Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability |
| Q94544744 | Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation |
| Q58747279 | Histone acetylation as a new mechanism for bilirubin-induced encephalopathy in the Gunn rat |
| Q35016934 | Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer |
| Q27021381 | Histone deacetylases and their role in motor neuron degeneration |
| Q36520153 | Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA. |
| Q36926069 | Inhibition of HDAC2 protects the retina from ischemic injury |
| Q47923208 | Manganese Control of Glutamate Transporters' Gene Expression |
| Q98224396 | Mitochondrial Dysfunction, Neurogenesis, and Epigenetics: Putative Implications for Amyotrophic Lateral Sclerosis Neurodegeneration and Treatment |
| Q47290734 | Neurodegenerative Disease Proteinopathies Are Connected to Distinct Histone Post-translational Modification Landscapes. |
| Q45814092 | Regional and cell-type specific distribution of HDAC2 in the adult mouse brain |
| Q91660695 | Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model |
| Q96649184 | Revisiting the complex architecture of ALS in Turkey: Expanding genotypes, shared phenotypes, molecular networks, and a public variant database |
| Q37712723 | Selection and Prioritization of Candidate Drug Targets for Amyotrophic Lateral Sclerosis Through a Meta-Analysis Approach |
| Q38361065 | Targeting histone deacetylases: a novel approach in Parkinson's disease |
| Q38094663 | Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities |
| Q90615812 | Temporal evolution of the microbiome, immune system and epigenome with disease progression in ALS mice |
| Q36179578 | Tissue-specific deregulation of selected HDACs characterizes ALS progression in mouse models: pharmacological characterization of SIRT1 and SIRT2 pathways. |
| Q38542939 | Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy |
| Q26862755 | Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques |
Search more.